These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33159633)

  • 1. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial.
    Rabaglio M; Sun Z; Maibach R; Giobbie-Hurder A; Ejlertsen B; Harvey VJ; Neven P; Láng I; Bonnefoi H; Wardley A; Ruepp B; Castiglione M; Coates AS; Gelber RD; Goldhirsch A; Colleoni M; Thürlimann B; Regan MM
    Breast Cancer Res Treat; 2021 Feb; 185(3):697-707. PubMed ID: 33159633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
    ; Mouridsen H; Giobbie-Hurder A; Goldhirsch A; Thürlimann B; Paridaens R; Smith I; Mauriac L; Forbes J; Price KN; Regan MM; Gelber RD; Coates AS
    N Engl J Med; 2009 Aug; 361(8):766-76. PubMed ID: 19692688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
    Regan MM; Neven P; Giobbie-Hurder A; Goldhirsch A; Ejlertsen B; Mauriac L; Forbes JF; Smith I; Láng I; Wardley A; Rabaglio M; Price KN; Gelber RD; Coates AS; Thürlimann B; ;
    Lancet Oncol; 2011 Nov; 12(12):1101-8. PubMed ID: 22018631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of the BIG 1-98 Trial: where do we stand?
    Joerger M; Thürlimann B
    Breast; 2009 Oct; 18 Suppl 3():S78-82. PubMed ID: 19914548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
    Mouridsen H; Keshaviah A; Coates AS; Rabaglio M; Castiglione-Gertsch M; Sun Z; Thürlimann B; Mauriac L; Forbes JF; Paridaens R; Gelber RD; Colleoni M; Smith I; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Dec; 25(36):5715-22. PubMed ID: 17998546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer.
    Giobbie-Hurder A; Price KN; Gelber RD; ;
    Clin Trials; 2009 Jun; 6(3):272-87. PubMed ID: 19528136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
    Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL
    J Natl Cancer Inst; 2005 Sep; 97(17):1262-71. PubMed ID: 16145047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98.
    Koeberle D; Thuerlimann B
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):55-66. PubMed ID: 17912636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.
    Crivellari D; Sun Z; Coates AS; Price KN; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens RJ; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Gladieff L; Rabaglio M; Smith IE; Chirgwin JH; Goldhirsch A
    J Clin Oncol; 2008 Apr; 26(12):1972-9. PubMed ID: 18332471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study.
    Colleoni M; Giobbie-Hurder A; Regan MM; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Láng I; Smith I; Chirgwin J; Pienkowski T; Wardley A; Price KN; Gelber RD; Coates AS; Goldhirsch A
    J Clin Oncol; 2011 Mar; 29(9):1117-24. PubMed ID: 21321298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
    Goss PE; Ingle JN; Pritchard KI; Robert NJ; Muss H; Gralow J; Gelmon K; Whelan T; Strasser-Weippl K; Rubin S; Sturtz K; Wolff AC; Winer E; Hudis C; Stopeck A; Beck JT; Kaur JS; Whelan K; Tu D; Parulekar WR
    N Engl J Med; 2016 Jul; 375(3):209-19. PubMed ID: 27264120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
    Chirgwin J; Sun Z; Smith I; Price KN; Thürlimann B; Ejlertsen B; Bonnefoi H; Regan MM; Goldhirsch A; Coates AS;
    Breast Cancer Res Treat; 2012 Jan; 131(1):295-306. PubMed ID: 21892704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial.
    Ruhstaller T; Giobbie-Hurder A; Colleoni M; Jensen MB; Ejlertsen B; de Azambuja E; Neven P; Láng I; Jakobsen EH; Gladieff L; Bonnefoi H; Harvey VJ; Spazzapan S; Tondini C; Del Mastro L; Veyret C; Simoncini E; Gianni L; Rochlitz C; Kralidis E; Zaman K; Jassem J; Piccart-Gebhart M; Di Leo A; Gelber RD; Coates AS; Goldhirsch A; Thürlimann B; Regan MM;
    J Clin Oncol; 2019 Jan; 37(2):105-114. PubMed ID: 30475668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial.
    Ewertz M; Gray KP; Regan MM; Ejlertsen B; Price KN; Thürlimann B; Bonnefoi H; Forbes JF; Paridaens RJ; Rabaglio M; Gelber RD; Colleoni M; Láng I; Smith IE; Coates AS; Goldhirsch A; Mouridsen HT
    J Clin Oncol; 2012 Nov; 30(32):3967-75. PubMed ID: 23045588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Mamounas EP; Bandos H; Lembersky BC; Jeong JH; Geyer CE; Rastogi P; Fehrenbacher L; Graham ML; Chia SK; Brufsky AM; Walshe JM; Soori GS; Dakhil SR; Seay TE; Wade JL; McCarron EC; Paik S; Swain SM; Wickerham DL; Wolmark N
    Lancet Oncol; 2019 Jan; 20(1):88-99. PubMed ID: 30509771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.